Aoife Brennan
Director/Board Member bij FIBROGEN, INC.
Vermogen: 51 833 $ op 30-04-2024
Actieve functies van Aoife Brennan
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
FIBROGEN, INC. | Director/Board Member | 05-08-2020 | - |
Synlogic Operating Co., Inc.
Synlogic Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA. | Director/Board Member | - | - |
Chief Executive Officer | 01-05-2018 | - | |
President | 01-05-2018 | - | |
Chief Tech/Sci/R&D Officer | 01-09-2016 | - | |
Cerevance, Inc.
Cerevance, Inc. Medical SpecialtiesHealth Technology Cerevance, Inc. provides pharmaceutical services. The firm discovers new treatments for central nervous system diseases. Its platform enables to profile specific brain cell types including both neurons and glial cells in mature human brain tissue. The company was founded by Bradley A. Margus and Mark Carlton in 2016 and is headquartered in Boston, MA. | Director/Board Member | 01-01-2020 | - |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Consultant / Advisor | - | - |
Loopbaan van Aoife Brennan
Eerdere bekende functies van Aoife Brennan
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
SYNLOGIC, INC. | Director/Board Member | 01-10-2018 | 09-03-2024 |
Chief Executive Officer | 10-05-2018 | 09-03-2024 | |
Chief Tech/Sci/R&D Officer | 01-09-2016 | 04-09-2019 | |
President | 10-05-2018 | 09-03-2024 | |
RA PHARMACEUTICALS, INC. | Director/Board Member | 25-09-2018 | 02-04-2020 |
Independent Dir/Board Member | 25-09-2018 | 02-04-2020 | |
BIOGEN INC. | Corporate Officer/Principal | 01-05-2011 | 01-08-2016 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | Corporate Officer/Principal | 01-01-2008 | 01-04-2011 |
Opleiding van Aoife Brennan
Trinity College Dublin | Doctorate Degree |
Harvard Medical School | Graduate Degree |
Statistieken
Internationaal
Verenigde Staten | 10 |
Ierland | 2 |
Operationeel
Director/Board Member | 5 |
Chief Executive Officer | 2 |
Chief Tech/Sci/R&D Officer | 2 |
Sectoraal
Health Technology | 8 |
Consumer Services | 3 |
Finance | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
BIOGEN INC. | Health Technology |
FIBROGEN, INC. | Health Technology |
SYNLOGIC, INC. | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | Health Technology |
Ra Pharmaceuticals, Inc.
Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Synlogic Operating Co., Inc.
Synlogic Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Cerevance, Inc.
Cerevance, Inc. Medical SpecialtiesHealth Technology Cerevance, Inc. provides pharmaceutical services. The firm discovers new treatments for central nervous system diseases. Its platform enables to profile specific brain cell types including both neurons and glial cells in mature human brain tissue. The company was founded by Bradley A. Margus and Mark Carlton in 2016 and is headquartered in Boston, MA. | Health Technology |
- Beurs
- Insiders
- Aoife Brennan
- Ervaring